Patent ID: 7989460

Claim:
A compound of the formula IIb: wherein: M is —CH— or —N—; nc is 0, 1 or 2; R 2c is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl; R 2d is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro; R 2a and R 2b are each independently selected from hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylsulphanyl, —NR 3a R 4a (wherein R 3a and R 4a , which may be the same or different, each represents hydrogen or C 1-3 alkyl), and Q 1 X 1 — wherein Q 1 is selected from one of the following groups: 1) —C 1-4 alkyl-Q 13 -C(O)—C 1-4 alkyl-Q 14 wherein Q 13 and Q 14 are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl, wherein Q 14 is linked to C 1-4 alkanoyl through a nitrogen atom; 2) Q 2 (wherein Q 2 is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl, which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C 2-4 alkanoylC 1-3 alkyl and optionally bears a further 1 or 2 substituents selected from C 2-5 alkenyl, C 2-5 alkynyl, C 1-6 fluoroalkyl, C 1-6 alkanoyl, C 2-4 alkanoylC 1-3 alkyl, aminoC 1-6 alkanoyl, C 1-4 alkylaminoC 1-6 alkanoyl, di(C 1-4 alkyl)aminoC 1-6 alkanoyl, C 1-6 -fluoroalkanoyl, carbamoyl, C 1-4 alkylcarbamoyl, di(C 1-4 alkyl)carbamoyl, carbamoylC 1-6 alkyl, C 1-4 alkylcarbamoylC 1-6 alkyl, di(C 1-4 alkyl)carbamoylC 1-6 alkyl, C 1-6 alkylsulphonyl, C 1-6 fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C 1-4 cyanoalkyl, C 1-4 alkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy, C 1-4 alkoxyC 1-4 alkyl, C 1-4 alkylsulphonylC 1-4 alkyl, C 1-4 alkoxycarbonyl, C 1-4 aminoalkyl, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 alkylaminoC 1-4 alkyl, di(C 1-4 alkyl)aminoC 1-4 alkyl, C 1-4 alkylaminoC 1-4 alkoxy, di(C 1-4 alkyl)aminoC 1-4 alkoxy and a group —(—O—) f (C 1-4 alkyl) g ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C 1-4 alkyl)); and 3) —C 1-5 alkylQ 2 (wherein Q 2 is as defined herein); and X 1 is O; and additionally wherein any C 1-5 alkyl group in Q 1 X 1 — which is linked to X 1 may bear one or more substituents selected from hydroxy, halogeno and amino; Za is —O— or —S—; with the proviso that at least one of R 2a and R 2b is Q 1 X 1 — wherein Q 1 and X 1 are as defined herein; or a pharmaceutically-acceptable salt thereof.